Caribou Biosciences (CRBU) Cash & Current Investments (2020 - 2026)

Caribou Biosciences (CRBU) has 7 years of Cash & Current Investments data on file, last reported at $117.6 million in Q1 2026.

• On a quarterly basis, Cash & Current Investments fell 43.58% year-over-year to $117.6 million in Q1 2026; TTM through Mar 2026 was $117.6 million, a 43.58% decrease from a year earlier, with the FY2025 full-year figure at $139.3 million, down 33.5% from the prior year.
• Cash & Current Investments for Q1 2026 stood at $117.6 million, down from $139.3 million in the prior quarter.
• Over the last five years, Cash & Current Investments for CRBU reached as high as $353.7 million in Q1 2022 and fell as low as $117.6 million in Q1 2026.
• Historically, Cash & Current Investments has averaged $245.9 million across 5 years, with a median of $247.7 million in 2022.
• Across the five-year window, Cash & Current Investments soared 162.44% in 2022 and tumbled 43.58% in 2026, its largest moves.
• Year by year, Cash & Current Investments stood at $247.7 million in 2022, then soared by 32.77% to $328.8 million in 2023, then plunged by 36.28% to $209.5 million in 2024, then slumped by 33.5% to $139.3 million in 2025, then fell by 15.58% to $117.6 million in 2026.
• Per Business Quant data, the three most recent Cash & Current Investments figures were $117.6 million in Q1 2026, $139.3 million in Q4 2025, and $147.3 million in Q3 2025.